医学
危险系数
哮喘
福莫特罗
减肥
内科学
恶化
置信区间
回顾性队列研究
体质指数
赛马鲁肽
队列研究
肥胖
临床试验
糖尿病
吸入器
观察研究
超重
肺活量测定
重症监护医学
比例危险模型
儿科
队列
阿巴塔克普
急诊医学
中止
呼吸系统
作者
Kristen A Staggers,Charles Minard,Meredith C McCormack,Katherine N. Cahill,Tianshi David Wu
标识
DOI:10.1093/ajrccm/aamag613
摘要
RATIONALE: Obesity is associated with poor asthma outcomes. GLP-1 and dual GLP-1/GIP receptor agonists induce weight loss and dampen airway inflammation independent of pathways currently targeted by biologics. OBJECTIVE: To compare differences in respiratory outcomes and weight loss between GLP-1-based medications and tezepelumab in asthma patients without diabetes. METHODS: A retrospective study was performed in a multi-institutional electronic health record database. Patients with specialist-treated, obesity-associated, moderate-to-severe asthma with at least one severe exacerbation in the prior year who initiated liraglutide, semaglutide, tirzepatide, or tezepelumab between January 1, 2022 and December 31, 2025 were identified. Prevalent diabetes was excluded. Patients were followed for subsequent exacerbations, rescue inhaler prescriptions, respiratory-related healthcare encounters, and time to greater than 10% loss in body mass index. Overlap weighting accounted for imbalance in baseline asthma and obesity characteristics. RESULTS: 2779 patients were identified, of whom 133 initiated liraglutide, 1770 semaglutide, 472 tirzepatide, and 404 tezepelumab. In weighted estimates, patients starting tirzepatide experienced a lower hazard of severe exacerbation compared to tezepelumab (weighted hazard ratio [wHR] 0.41; 95% confidence interval [CI] 0.24-0.70); those starting semaglutide had a similar hazard (wHR 0.99; 95% CI 0.70-1.39). Tirzepatide and semaglutide initiators attained >10% reduction in BMI sooner, had less need for rescue inhalers, and had fewer subsequent respiratory-related encounters compared to tezepelumab. CONCLUSIONS: GLP-1-based medications, and in particular dual-incretin GLP-1/GIP receptor agonists, may have comparable effectiveness to biologic therapy among patients with associated obesity without diabetes. Clinical trials are necessary to validate findings in this observational study.
科研通智能强力驱动
Strongly Powered by AbleSci AI